Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viracta Therapeutics (VIRX)
NASDAQ:VIRX
Viracta Therapeutics (VIRX) Stock Price & Analysis
833 Followers
VIRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.43 - $1.68
Previous Close$0.64
Volume128.40K
Average Volume (3M)102.58K
Market Cap
$25.20M
Enterprise Value-$12.19M
Total Cash (Recent Filing)$62.95M
Total Debt (Recent Filing)$25.56M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 07, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding39,272,434
10 Day Avg. Volume142,661
30 Day Avg. Volume102,575
Standard Deviation0.29
R-Squared0.00448
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$6.50Price Target Upside864.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Viracta Therapeutics News
PremiumCompany Announcements
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTreatment with nana-val resulted in a 50% objective response rate in PTCL patients.
Comparative EfficacyNana-val's response rates appear meaningfully better than those achieved by current treatments such as belinostat, romidepsin, and pralatrexate.
Regulatory EngagementThe company has engaged with the Japanese PMDA, receiving endorsement to enroll patients in the NAVAL-1 trial without additional studies.
Bears Say
Clinical DataA Nstat monotherapy cohort, required by the FDA, showed limited efficacy with only a 10% overall response rate in treated patients.
Drug SafetyInvestor concerns arose due to a serious adverse event related to the drug that resulted in a patient's death from pancytopenia and sepsis.
Regulatory RisksRisks include potential inability to generate further favorable clinical data, failure to secure accelerated FDA approval, and possible poorer market uptake due to competition or other factors.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VIRX FAQ
What was Viracta Therapeutics’s price range in the past 12 months?
Viracta Therapeutics lowest stock price was $0.43 and its highest was $1.68 in the past 12 months.
What is Viracta Therapeutics’s market cap?
Currently, no data Available
When is Viracta Therapeutics’s upcoming earnings report date?
Viracta Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 53 days.
How were Viracta Therapeutics’s earnings last quarter?
Viracta Therapeutics released its earnings results on May 09, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.122.
Is Viracta Therapeutics overvalued?
According to Wall Street analysts Viracta Therapeutics’s price is currently Undervalued.
Does Viracta Therapeutics pay dividends?
Viracta Therapeutics does not currently pay dividends.
What is Viracta Therapeutics’s EPS estimate?
Viracta Therapeutics’s EPS estimate is -$0.36.
How many shares outstanding does Viracta Therapeutics have?
Viracta Therapeutics has 39,272,434 shares outstanding.
What happened to Viracta Therapeutics’s price movement after its last earnings report?
Viracta Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went down -7.317%.
Which hedge fund is a major shareholder of Viracta Therapeutics?
Among the largest hedge funds holding Viracta Therapeutics’s share is Aisling Capital Management LP. It holds Viracta Therapeutics’s shares valued at 294K.
---
Viracta Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (864.68% Upside)
$6.50 (864.68% Upside)
Blogger Sentiment
Bullish
VIRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.58%
12-Months-Change
Fundamentals
Return on Equity
-154.33%
Trailing 12-Months
Asset Growth
-51.81%
Trailing 12-Months
Company Description
Viracta Therapeutics
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
---
VIRX Stock 12 Month Forecast
Average Price Target
$6.50
▲(864.68% Upside)
Technical Analysis
Best Analysts Covering VIRX
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-37.01%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -37.01% per trade.
---